Investing.com - MoonLake Immunotherapeutics (NASDAQ: MLTX) reported third quarter EPS of $-0.18, $0.05 better than the analyst estimate of $-0.23. Revenue for the quarter came in at $0 versus the consensus estimate of $0.
MoonLake Immunotherapeutics's stock price closed at $37.40. It is down -35.10% in the last 3 months and up 317.77% in the last 12 months.
MoonLake Immunotherapeutics saw 2 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See MoonLake Immunotherapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, MoonLake Immunotherapeutics's Financial Health score is "fair performance".
Check out MoonLake Immunotherapeutics's recent earnings performance, and MoonLake Immunotherapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar